Clavicular Peptide Stack | Retatrutide + Melanotan II + HGH Fragment | QSC
QSC RESEARCH COMPOUND GUIDE
RetatrutideMelanotan IIBPC-157HGH Fragment 176-191Janoshik COA All Components
The Clavicular Peptide Stack — Research Analysis
The Clavicular stack refers to the multi-compound research protocol discussed publicly by social media influencer Clavicular, involving retatrutide, melanotan II, HGH fragment 176-191, and BPC-157. This page provides a research-focused breakdown of each compound — mechanisms, clinical data, and what the scientific literature says. QSC supplies all compounds strictly for laboratory research purposes.
Compounds in the Stack
Retatrutide — Triple GLP-1R/GIPR/GCGR Agonist
The most potent weight loss compound in clinical development. Phase 2 data: 24.2% mean body weight reduction at 48 weeks. Triple agonism: GLP-1R (appetite), GIPR (enhanced adipocyte effects), GCGR (hepatic fat mobilisation + brown adipose activation). Highest weight reduction of any pharmacological agent in human trials.
Melanotan II — MC1R/MC4R/MC3R Agonist
Activates melanocortin receptors: MC1R for melanogenesis (tanning), MC4R for appetite suppression and sexual function, MC3R for energy balance. Relevant to the looksmaxxing context: fat loss support (MC4R) + skin appearance (MC1R melanin).
HGH Fragment 176-191 — Selective Lipolytic Fragment
C-terminal GH fragment selectively activates lipolysis without IGF-1 axis engagement. No insulin resistance, no water retention. Adds direct adipose mobilisation to the GLP-1-mediated appetite suppression from retatrutide — complementary non-overlapping mechanism.
BPC-157 — Tissue Repair / GI Protection
NOS/VEGF/EGF activation promoting angiogenesis and fibroblast recruitment. GI cytoprotection. In the stack context: recovery support and GI tract protection during the protocol. Independent mechanism from all other compounds.
The Clavicular stack is a multi-compound protocol discussed publicly by social media influencer Clavicular, involving retatrutide, melanotan II, HGH fragment 176-191, and BPC-157. QSC provides research analysis of each compound.
What is retatrutide and why is it the core compound?
Retatrutide is a triple GLP-1R/GIPR/GCGR agonist in Phase 2/3 trials. Phase 2 data: 24.2% body weight reduction at 48 weeks — the highest of any pharmacological agent in human trials.
Does QSC sell the Clavicular stack compounds?
Yes. QSC stocks retatrutide, melanotan II, HGH fragment 176-191, and BPC-157 — all with domestic USA shipping and Janoshik COA.
What peptides is Clavicular on?
Clavicular has publicly discussed using retatrutide, melanotan II, HGH fragment 176-191, and BPC-157 — the compounds analysed on this page. QSC provides research information only.
